August 2024

Sable Therapeutics, a portfolio company of Turret Capital Management, announces licensing agreement with Columbia University NEW YORK, Aug. 9, 2024 /PRNewswire/ — Sable Therapeutics, an innovative early stage drug development company focused on pioneering fat reduction therapies, today announc

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: